Loading...
XSTO
S2M
Market cap808kUSD
Apr 09, Last price  
0.01SEK
1D
-5.00%
1Q
0.00%
IPO
-99.96%
Name

S2Medical AB (publ)

Chart & Performance

D1W1MN
P/E
1.38
P/S
0.53
EPS
0.01
Div Yield, %
—
Shrs. gr., 5y
64.57%
Rev. gr., 5y
36.91%
Revenues
15m
+113.82%
1,534,524340,000844,0001,495,5823,098,45925,615,6127,699,7864,670,2026,971,34614,906,000
Net income
6m
P
2,796-1,195,000-5,377,000-10,730,770-18,537,025-15,082,085-20,322,655-31,224,206-22,707,4575,771,000
CFO
3m
P
0-3,031,000-5,846,000-12,753,554-17,103,985-12,749,160-19,665,185-28,131,269-16,519,8843,122,000

Profile

S2Medical AB (publ) develops, produces, and sells wound healing products for burns and chronic wounds. It offers INSTAQRETT, a sterile single use mechanical debridement tool; EPIPROTECT SafeStop for blood stilling; Instagraft, a single-use medical device for the treatment of chronic and complicated wounds; EPIPROTECT tissue substitutes; and washable, waterproof, and self-adhesive bandages under the INSTABIND brand name. The company also distributes Silverlon dressings that deliver silver ions into the wound. In addition, it operates wound healing center under the S2Clinic name. The company was founded in 2013 and is headquartered in Linköping, Sweden.
URL
https://www.s2m.se/
IPO date
Nov 28, 2018
Employees
20
Domiciled in
SE
Incorporated in
SE

Valuation

Title
SEK in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
14,906
113.82%
6,971
49.27%
4,670
-39.35%
Cost of revenue
766
2,540
100
Unusual Expense (Income)
NOPBT
14,140
4,431
4,570
NOPBT Margin
94.86%
63.56%
97.86%
Operating Taxes
1,768
Tax Rate
38.68%
NOPAT
14,140
4,431
2,802
Net income
5,771
-125.41%
(22,707)
-27.28%
(31,224)
53.64%
Dividends
Dividend yield
Proceeds from repurchase of equity
4,369
22,000
22,512
BB yield
-74.32%
-232.56%
-48.05%
Debt
Debt current
(231)
Long-term debt
Deferred revenue
Other long-term liabilities
1,000
1
1,772
Net debt
(1,005)
(1,517)
(3,954)
Cash flow
Cash from operating activities
3,122
(16,520)
(28,131)
CAPEX
(634)
(1,155)
(1,899)
Cash from investing activities
(634)
(1,155)
(1,762)
Cash from financing activities
3,791
15,470
24,137
FCF
3,765
9,389
9,884
Balance
Cash
1,005
1,517
3,723
Long term investments
Excess cash
260
1,168
3,489
Stockholders' equity
11,851
(108,140)
(97,368)
Invested Capital
11,543
109,798
104,083
ROIC
23.31%
4.14%
2.98%
ROCE
119.80%
267.25%
68.05%
EV
Common stock shares outstanding
559,858
157,666
68,898
Price
0.01
-82.50%
0.06
-91.18%
0.68
-87.05%
Market cap
5,879
-37.86%
9,460
-79.81%
46,851
-84.68%
EV
4,874
7,943
142,167
EBITDA
15,172
6,165
6,488
EV/EBITDA
0.32
1.29
21.91
Interest
20
7,444
1,768
Interest/NOPBT
0.14%
168.00%
38.68%